Current status on development of steroids as anticancer agents

被引:177
|
作者
Gupta, Atul [1 ]
Kumar, B. Sathish [1 ]
Negi, Arvind S. [1 ]
机构
[1] CSIR, CIMAP, Dept Med Chem, Lucknow 226015, Uttar Pradesh, India
关键词
Antiestrogens; Aromatase inhibitors; Hormone dependent cancers; 17 beta-Hydroxysteroids dehydrogenase inhibitors; Steroid conjugates; Steroid sulfatase inhibitors; BREAST-CANCER CELLS; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-1 INHIBITORS; POTENTIAL AROMATASE INHIBITORS; IN-VITRO CHARACTERIZATION; RECEPTOR-ALPHA AFFINITY; BIOLOGICAL EVALUATION; D-RING; ANTIPROLIFERATIVE ACTIVITY; CHEMICAL-SYNTHESIS; ESTRONE SULFATE;
D O I
10.1016/j.jsbmb.2013.05.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Steroids are important biodynamic agents. Their affinities for various nuclear receptors have been an interesting feature to utilize them for drug development particularly for receptor mediated diseases. Steroid biochemistry and its crucial role in human physiology, has attained importance among the researchers. Recent years have seen an extensive focus on modification of steroids. The rational modifications of perhydrocyclopentanophenanthrene nucleus of steroids have yielded several important anticancer lead molecules. Exemestane, SR16157, fulvestrant and 2-methoxyestradiol are some of the successful leads emerged on steroidal pharmacophores. The present review is an update on some of the steroidal leads obtained during past 25 years. Various steroid based enzyme inhibitors, antiestrogens, cytotoxic conjugates and steroidal cytotoxic molecules of natural as well as synthetic origin have been highlighted. This article is part of a Special Issue entitled "Synthesis and biological testing of steroid derivatives as inhibitors". (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:242 / 270
页数:29
相关论文
共 50 条
  • [1] Current status of development of anticancer agents in Japan
    Morita, Tomohiro
    Hori, Akiko
    Narimatatsu, Hiroto
    Tanimoto, Tetsuya
    Kami, Masahiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 87 (05) : 484 - 489
  • [2] Current status of development of anticancer agents in Japan
    Tomohiro Morita
    Akiko Hori
    Hiroto Narimatatsu
    Tetsuya Tanimoto
    Masahiro Kami
    [J]. International Journal of Hematology, 2008, 87 : 484 - 489
  • [3] Erratum to: Current status of development of anticancer agents in Japan
    Tomohiro Morita
    Akiko Hori
    Hiroto Narimatsu
    Tetsuya Tanimoto
    Masahiro Kami
    [J]. International Journal of Hematology, 2008, 87 (5) : 490 - 490
  • [4] Current status of carbazole hybrids as anticancer agents
    Wang, Gangqiang
    Sun, Shaofa
    Guo, Hua
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 229
  • [5] Current development of mTOR inhibitors as anticancer agents
    Sandrine Faivre
    Guido Kroemer
    Eric Raymond
    [J]. Nature Reviews Drug Discovery, 2006, 5 : 671 - 688
  • [6] Current development of mTOR inhibitors as anticancer agents
    Faivre, Sandrine
    Kroemer, Guido
    Raymond, Eric
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 671 - 688
  • [7] Natural Products as Anticancer Agents: Current Status and Future Perspectives
    Naeem, Abid
    Hu, Pengyi
    Yang, Ming
    Zhang, Jing
    Liu, Yali
    Zhu, Weifeng
    Zheng, Qin
    [J]. MOLECULES, 2022, 27 (23):
  • [9] Development and Current Status of Unconventional Platinum Anticancer Complexes
    Abu-Surrah, Adnan Salim
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (02) : 203 - 211
  • [10] Current development of the second generation of mTOR inhibitors as anticancer agents
    Zhou, Hong-Yu
    Huang, Shi-Le
    [J]. CHINESE JOURNAL OF CANCER, 2012, 31 (01) : 8 - 18